title: Comparison of clinical features and immunological parameters of patients with dehydrating diarrhoea infected with Inaba or Ogawa serotypes of Vibrio cholerae O1.
abstract: Vibrio cholerae O1, Ogawa and Inaba serotypes, both cause severe cholera. We compared clinical and immunological features in patients in Bangladesh infected with these 2 serotypes. Blood was collected from hospitalized Ogawa (N=146) or Inaba (N=191) patients at the acute stage (day 2) and 5 and 19 days later. Ogawa patients were younger than Inaba, presented with shorter duration of diarrhoea, and had more frequent abdominal pain, vomiting and need for intravenous fluids (p<0.05). Inaba patients more frequently had dark-field positive stools (p<0.01). Inaba strains were more susceptible to tetracycline and erythromycin than Ogawa strains (p<0.001). Ogawa infection produced higher plasma vibriocidal as well as IgG responses to cholera toxin B subunit, toxin-coregulated pilus subunit and lipopolysaccharide (LPS); higher IgA responses to LPS in 'antibody in lymphocyte supernatant' (ALS) specimens were also seen. These results suggest that a cholera vaccine based on the Ogawa serotype needs to be further investigated.
authors.affiliation: Laboratory Sciences Division, International Centre for Diarrhoeal Disease Research, Dhaka, Bangladesh.
authors.forename: Ashraful I
authors.initials: AI
authors.lastname: Khan
authors.forename: Fahima
authors.initials: F
authors.lastname: Chowdhury
authors.forename: Jason B
authors.initials: JB
authors.lastname: Harris
authors.forename: Regina C
authors.initials: RC
authors.lastname: Larocque
authors.forename: Abu S G
authors.initials: AS
authors.lastname: Faruque
authors.forename: Edward T
authors.initials: ET
authors.lastname: Ryan
authors.forename: Stephen B
authors.initials: SB
authors.lastname: Calderwood
authors.forename: Firdausi
authors.initials: F
authors.lastname: Qadri
mesh_terms: D000293:Adolescent; D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D000900:Anti-Bacterial Agents / Q000494:pharmacology; D000907:Antibodies, Bacterial / Q000097:blood*; D001459:Bangladesh; D002648:Child; D002675:Child, Preschool; D002771:Cholera / Q000150:complications / Q000276:immunology* / Q000382:microbiology / Q000473:pathology*; D002772:Cholera Toxin / Q000276:immunology; D003681:Dehydration / Q000209:etiology* / Q000473:pathology*; D004917:Erythromycin / Q000494:pharmacology; D005243:Feces / Q000382:microbiology; D005260:Female; D006801:Humans; D007074:Immunoglobulin G / Q000097:blood; D007223:Infant; D008070:Lipopolysaccharides / Q000276:immunology; D008297:Male; D008826:Microbial Sensitivity Tests; D050296:Microbial Viability; D008875:Middle Aged; D012703:Serotyping; D013752:Tetracycline / Q000494:pharmacology; D041241:Vibrio cholerae O1 / Q000145:classification / Q000187:drug effects / Q000276:immunology* / Q000302:isolation & purification*; D055815:Young Adult
chemical_list: D000900:Anti-Bacterial Agents; D000907:Antibodies, Bacterial; D007074:Immunoglobulin G; D008070:Lipopolysaccharides; D004917:Erythromycin; D002772:Cholera Toxin; D013752:Tetracycline